193 related articles for article (PubMed ID: 37704431)
21. Low serum docosahexaenoic acid is associated with progression of coronary atherosclerosis in statin-treated patients with diabetes mellitus: results of the treatment with statin on atheroma regression evaluated by intravascular ultrasound with virtual histology (TRUTH) study.
Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Terashima M; Michishita I
Cardiovasc Diabetol; 2014 Jan; 13():13. PubMed ID: 24410834
[TBL] [Abstract][Full Text] [Related]
22. Pretreatment with and ongoing use of omega-3 fatty acid ethyl esters reduce the slow-flow phenomenon and prevent in-stent restenosis in patients undergoing carotid artery stenting.
Nakagawa I; Park HS; Yokoyama S; Wada T; Yamada S; Motoyama Y; Kichikawa K; Nakase H
J Vasc Surg; 2017 Jul; 66(1):122-129. PubMed ID: 28359716
[TBL] [Abstract][Full Text] [Related]
23. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
[TBL] [Abstract][Full Text] [Related]
24. Administration of eicosapentaenoic acid may alter high-density lipoprotein heterogeneity in statin-treated patients with stable coronary artery disease: A 6-month randomized trial.
Tani S; Matsuo R; Yagi T; Matsumoto N
J Cardiol; 2020 Mar; 75(3):282-288. PubMed ID: 31543378
[TBL] [Abstract][Full Text] [Related]
25. Association of Decreased Docosahexaenoic Acid Level After Statin Therapy and Low Eicosapentaenoic Acid Level with In-Stent Restenosis in Patients with Acute Coronary Syndrome.
Yagi S; Kondo D; Ise T; Fukuda D; Yamaguchi K; Wakatsuki T; Kawabata Y; Ito H; Saijo Y; Seno H; Sutou K; Ueno R; Todoroki T; Kusunose K; Matsuura T; Tobiume T; Yamada H; Soeki T; Shimabukuro M; Aihara KI; Akaike M; Sata M
J Atheroscler Thromb; 2019 Mar; 26(3):272-281. PubMed ID: 30135329
[TBL] [Abstract][Full Text] [Related]
26. Cardiovascular effects of omega-3 fatty acids: Hope or hype?
Jo SH; Han SH; Kim SH; Eckel RH; Koh KK
Atherosclerosis; 2021 Apr; 322():15-23. PubMed ID: 33706079
[TBL] [Abstract][Full Text] [Related]
27. Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma.
Nishio R; Shinke T; Otake H; Nakagawa M; Nagoshi R; Inoue T; Kozuki A; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Shite J; Hirata K
Atherosclerosis; 2014 May; 234(1):114-9. PubMed ID: 24637411
[TBL] [Abstract][Full Text] [Related]
28. The triglyceride-lowering effects of a modest dose of docosahexaenoic acid alone versus in combination with low dose eicosapentaenoic acid in patients with coronary artery disease and elevated triglycerides.
Schwellenbach LJ; Olson KL; McConnell KJ; Stolcpart RS; Nash JD; Merenich JA;
J Am Coll Nutr; 2006 Dec; 25(6):480-5. PubMed ID: 17229894
[TBL] [Abstract][Full Text] [Related]
29. The Ratio of Eicosapentaenoic Acid (EPA) to Arachidonic Acid may be a Residual Risk Marker in Stable Coronary Artery Disease Patients Receiving Treatment with Statin Following EPA Therapy.
Tani S; Nagao K; Kawauchi K; Yagi T; Atsumi W; Matsuo R; Hirayama A
Am J Cardiovasc Drugs; 2017 Oct; 17(5):409-420. PubMed ID: 28634822
[TBL] [Abstract][Full Text] [Related]
30. Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease.
Nozue T; Yamamoto S; Tohyama S; Fukui K; Umezawa S; Onishi Y; Kunishima T; Sato A; Nozato T; Miyake S; Takeyama Y; Morino Y; Yamauchi T; Muramatsu T; Hibi K; Michishita I
J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):320-6. PubMed ID: 23324995
[TBL] [Abstract][Full Text] [Related]
31. Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki KC; Dicklin MR
Curr Opin Cardiol; 2020 Jul; 35(4):417-422. PubMed ID: 32412960
[TBL] [Abstract][Full Text] [Related]
32. Which has the stronger impact on coronary artery disease, eicosapentaenoic acid or docosahexaenoic acid?
Iwamatsu K; Abe S; Nishida H; Kageyama M; Nasuno T; Sakuma M; Toyoda S; Inoue T
Hypertens Res; 2016 Apr; 39(4):272-5. PubMed ID: 26739870
[TBL] [Abstract][Full Text] [Related]
33. The effect of omega-3 fatty acids on coronary atherosclerosis quantified by coronary computed tomography angiography.
Feuchtner G; Langer C; Barbieri F; Beyer C; Dichtl W; Friedrich G; Schgoer W; Widmann G; Plank F
Clin Nutr; 2021 Mar; 40(3):1123-1129. PubMed ID: 32778459
[TBL] [Abstract][Full Text] [Related]
34. Recent Clinical Trials Shed New Light on the Cardiovascular Benefits of Omega-3 Fatty Acids.
Kris-Etherton PM; Richter CK; Bowen KJ; Skulas-Ray AC; Jackson KH; Petersen KS; Harris WS
Methodist Debakey Cardiovasc J; 2019; 15(3):171-178. PubMed ID: 31687095
[TBL] [Abstract][Full Text] [Related]
35. A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.
Watanabe T; Ando K; Daidoji H; Otaki Y; Sugawara S; Matsui M; Ikeno E; Hirono O; Miyawaki H; Yashiro Y; Nishiyama S; Arimoto T; Takahashi H; Shishido T; Miyashita T; Miyamoto T; Kubota I;
J Cardiol; 2017 Dec; 70(6):537-544. PubMed ID: 28863874
[TBL] [Abstract][Full Text] [Related]
36. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.
Nicholls SJ; Lincoff AM; Garcia M; Bash D; Ballantyne CM; Barter PJ; Davidson MH; Kastelein JJP; Koenig W; McGuire DK; Mozaffarian D; Ridker PM; Ray KK; Katona BG; Himmelmann A; Loss LE; Rensfeldt M; Lundström T; Agrawal R; Menon V; Wolski K; Nissen SE
JAMA; 2020 Dec; 324(22):2268-2280. PubMed ID: 33190147
[TBL] [Abstract][Full Text] [Related]
37. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
38. The ratio of serum n-3 to n-6 polyunsaturated fatty acids is associated with diabetes mellitus in patients with prior myocardial infarction: a multicenter cross-sectional study.
Takahashi M; Ando J; Shimada K; Nishizaki Y; Tani S; Ogawa T; Yamamoto M; Nagao K; Hirayama A; Yoshimura M; Daida H; Nagai R; Komuro I
BMC Cardiovasc Disord; 2017 Jan; 17(1):41. PubMed ID: 28125968
[TBL] [Abstract][Full Text] [Related]
39. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B
Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322
[TBL] [Abstract][Full Text] [Related]
40. New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Preston Mason R
Curr Atheroscler Rep; 2019 Jan; 21(1):2. PubMed ID: 30637567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
